THE NEWEST STRAINS OF THE VIRUS ARE CAUSING A SURGE THIS SEASON, AND EXPERTS SAY IT’S IMPORTANT TO GET IMMUNIZED, ESPECIALLY IF YOU’RE AGE 65 OR OLDER.[i],[ii],[iii]

HERE NOW TO HELP CLARIFY LINGERING CONFUSION AROUND COVID-19 AND VACCINATION ARE PHARMACIST JOHN BECKNER AND SILVIA TAYLOR, CHIEF CORPORATE AFFAIRS AND ADVOCACY OFFICER AT NOVAVAX.

BIO:
John O. Beckner, R.Ph.

John is a pharmacist consultant with the National Community Pharmacists Association. Most recently, he served NCPA as Senior Director of Strategic Initiatives where he helped independent community pharmacies develop diversified revenue streams and maximize patient care activities. In his current role, John continues to be involved in several diabetes and immunization related activities, and he hosts Independent Rx Forum, NCPA’s podcast. He is a staunch supporter of innovative community pharmacy practice, especially with respect to immunizations. During his tenure as Director of Pharmacy and Health Services for Ukrop’s Super Markets, the company received numerous awards for excellence in immunizations, including the Immunization Champion and Pinnacle Awards from APhA.  John is a member of the Virginia Pharmacists Association, of which he served as president in 1996-1997. He received the 2014 APhA-APPM Distinguished Achievement Award in Pharmacy Management and the 2015 Bowl of Hygeia Award for outstanding community service, sponsored by APhA and NASPA. Most recently John received the Ed. D. Spearbeck Virgina Pharmacist Service Award for 2024.
John holds a Bachelor of Arts degree in biology from Wake Forest University and a Bachelor of Science degree in pharmacy from VCU/ MCV. He is on the board of directors of the Virginia Pharmacists Association Research and Education Foundation, the Board of Trustees of the MCV Foundation, and the VCU School of Pharmacy National Advisory Council.  John has served on the board of the Central Virginia Chapter of the Juvenile Diabetes Research Foundation (JDRF), the board of CrossOver Healthcare Ministry, the Health Practitioners Monitoring Committee for the Virginia Department of Health Professions, the board of Health Quality Innovators, and the Virginia Board of Pharmacy. John serves on several industry advisory boards including the Novavax Advisory Board and the Drug Store News Editorial Advisory Board. He is a luminary for CPESN VA and has been involved with the network since its inception.
John and his wife Pam have 3 children, 2 grandchildren, and 2 chocolate rescue labs!

Silvia Taylor
Executive Vice President,
Chief Corporate Affairs and Advocacy Officer
Silvia Taylor is the Executive Vice President and Chief Corporate Affairs and Advocacy Officer at Novavax. In her capacity, Ms. Taylor oversees both external and internal communications, government affairs, public policy, patient advocacy, corporate reputation, global corporate digital experience and engagement, and corporate responsibility. With a career spanning over 25 years in the pharmaceutical, biotech, and public health sectors, she brings a wealth of experience in commercial, corporate, and financial communications to her leadership role. Ms. Taylor’s diverse background includes marketing blockbuster and specialty pharmaceuticals, product launches, capital raising, and holding key positions in global investor relations and corporate affairs at prominent biopharmaceutical firms such as Pfizer, MedImmune, Sucampo, and Autolus.
Originally from Argentina, Ms. Taylor holds a Master of Business Administration degree from Columbia University and a Bachelor of Arts in foreign affairs from the University of Virginia. She also serves on the Board of Directors for the Maryland Technology Council.

The post THE NEWEST STRAINS OF THE VIRUS ARE CAUSING A SURGE THIS SEASON appeared first on Good News!.

www.goodnewsbroadcast.com, www.youtube.com/goodnewsbroadcast and www.goodnewsplanet.TV… Wow… how time flies when you are having a good time! 

Over 6,500 shows, many with you, our loyal members in them, sharing the Good that you all do…what an honor every time we add another story of someone doing good. The people of the world are Good and most of the world lives in peace and freedom…let’s realize this reality and not let the “negative media news” change our minds to the fact that most people aren’t “mentally ill” enough to hurt themselves or anyone else. 

Milestone Broadcast Corporation is up-beat, not beat-up, life affirming, thought provoking good news, entertainment, events, products and marketing services.

Please join our up-coming International Day of Peace & Ecology in Times Square for our LIVE Solar/Battery Broadcast on September 21st. Mark your calendars now and spread the world for our united www.pausetheworldforpeace.org, our nonprofit humanitarian project from Good News Corporation. Once again, here is the link to our 6 Hour Earth & Water Series from April 22 in Times Square:

Earth & Water Day from

Times Square April 22, 2023.

A Six-Hour Series.

We wanted to share two Central Park stories that we did yesterday, 6/29/23 in honor of our 25th Anniversary and our Peace & Ecology efforts, especially because we started our International Day of Peace events in Central Park in 2002. We hope that you enjoy them: 

Central Park, beautiful artwork on the ground, Peace, Love, Positivity, …Save Our Planet, NY Amanda and Rey

Central Park, beautiful artwork on the ground, Peace, Love, Positivity…Save Our Planet, NY Amanda and Rey

For the Podcast click the link below

Central Park, beautiful artwork on the ground, Peace, Love, Positivity… Save Our Planet, NY Amanda and Rey

To watch story on Youtube.com/GoodNewsBroadcast click the link below

Central Park, beautiful artwork on the ground, Peace, Love, Positivity…Save Our Planet…

Shakespeare Garden in Central Park with quotes and the Swedish Marionette Cottage…  gorgeous.

Shakespeare Garden in

Central Park with quotes and

The Swedish Marionette

Cottage…Gorgeous.

For the Podcast click the link below

Shakespeare Garden in Central Park with quotes and The Swedish Marionette Cottage…Gorgeous.

To watch story on Youtube.com/GoodNewsBroadcast click the link below

Shakespeare Garden in

Central Park with quotes and

The Swedish Marionette

Cottage…Gorgeous.

As mentioned, this is Milestone Broadcast Corporations 25th Anniversary and we have created over 7,000 shows, print stories and Podcasts… over 1,500 corporations and non-profits are represented. Many of these shows, stories and Podcasts, over 30% are on health & wellness and have saved peoples lives. Go to www.GoodNewsPlanet.TV, www.youtube.com/GoodNewsBroadcast and to listen to the Podcasts go to: https://www.spreaker.com/user/11258065

Here is a story about HS, an auto-immune disease brought to us by Novartis, 1 in a 100 suffer from this painful disease.

Documentary premiere at Tribeca Film Festival about 29-year old influencer, filmmaker and advocate Jasmine IVANNA Espy. She’s also the producer of “The Beacons: Illuminating HS Stories,” a new docuseries from Novartis that highlights her story and the stories of five other people living with hidradenitis suppurativa (HS)

Lastly, please join and introduce us to potential donors/sponsors who can help us fund our nonprofit 501 C 3 tax deductible www.pausetheworldforpeace.org  upcoming, International Day of Peace & Ecology: September 21, 2023. Times Square and the World LIVE Broadcast.   We are presenting this major event to funders to create one of the most important International Day of Peace & Ecology Events in the world. We plan to broadcast with Solar/Battery Power, Utilize Billboards in Times Square, major public relations campaign with our partners UNIFY, AY Young Battery Tour, We the World and others soon to be announced. Any suggestions, for donors, advertisers please let us know ASAP. Thanks with Peace & Love. Go to: https://goodnewsplanet.com/pausetheworld/peace-day-donations/ or call Paul 212 647 1212.  

LET’S GROW TOGETHER. GOOD NEWS MOTTO: ALL WE ARE IS WHAT WE ARE WITH EACH OTHER. ZEAL

For more information contact: 

Reverend Paul Sladkus, All Faiths and Spiritual 212 647 1212

New York, NY, Montauk, NY

PS – SPECIAL OPPORTUNITY FOR OUR FRIENDS AND MEMBERS: Looking for a vacation rental, SHORT TERM, in Montauk, here is our listing https://goodnewsplanet.com/montauk-manor-rental-suite-403-paul-sladkus/ call me. Paul 917 687 1790

The post GoodNewsLetter: July 4th, Good News Broadcasts 25th Anniversary, A Day for Peace, Independence & Freedom appeared first on Good News!.

There is now a new treatment option for the estimated 2 million people in the United States living with moderate-to-severe plaque psoriasis1,2,3 whose symptoms may make day-to-day life more challenging. For those that aren’t familiar with psoriasis, it is a widely prevalent, chronic, systemic immune-mediated disease.4

And up to 90% of patients with psoriasis have psoriasis vulgaris, also known as plaque psoriasis,5 which is characterized by distinct round or oval plaques typically covered by silvery-white scales.

One of the challenges that both doctors and patients face is that despite the availability of therapies, many people living with plaque psoriasis in the United States are untreated or undertreated.5,6

But good news has arrived. The U.S. Food and Drug Administration (FDA) has officially approved a new treatment for adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

Dr. April Armstrong, dermatologist and clinical investigator in one of the treatment’s trials and Associate Dean and Professor of Dermatology at the University of Southern California, alongside Leah M. Howard, J.D., President and CEO of the National Psoriasis Foundation, will discuss the impact of psoriasis and a new, FDA-approved oral treatment for moderate-to-severe plaque psoriasis. *

*Dr. April Armstrong and Leah Howard are paid spokespeople and are being compensated for their time.

Interview is courtesy: Bristol Myers Squibb

1. Armstrong AW, Mehta MD, Schupp CW, Gondo GC, Bell SJ, Griffiths CEM. Psoriasis prevalence in adults in the United States. JAMA Dermatol.2021;157(8):940-946. doi:10.1001/jamadermatol.2021.2007

2 Armstrong AW, Read C. Pathophysiology, clinical presentation, and treatment of psoriasis: a review. JAMA. 2020;323(19):1945-1960. doi:10.1001/jama.2020.4006

3 Armstrong et al. Undertreatment, Treatment Trends, and Treatment Dissatisfaction Among Patients With Psoriasis and Psoriatic Arthritis in the United States: Findings From the National Psoriasis Foundation Surveys, 2003-2011. JAMA Dermatol. 2013;149(10):1180–1185.
4. Armstrong AW, Schupp C, Wu J, Bebo B. Quality of life and work productivity impairment among psoriasis patients: findings from the National Psoriasis Foundation survey data 2003–2011. PloS One. 2012;7(12):e52935.

5. Menter A, Gottlieb A, Feldman SR, Van Voorhees AS et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol. 2008 May;58(5):826-50.

6. Lebwohl M, Langley RG, Paul C, et al. Evolution of patient perceptions of psoriatic disease: results from the Understanding Psoriatic Disease Leveraging Insights for Treatment (UPLIFT) survey. Dermatol Ther (Heidelb). 2022;12(1):61-78. doi:10.1007/s13555-021-00635-4

#aprilarmstrong #leahhoward #plaquepsoriasis #psoriasis #treatment #immunedisease #prevalent #chronic #systemicdisease #clinicaltreatment

The post PEOPLE WITH THE SKIN CONDITION KNOWN AS MODERATE-TO-SEVERE PLAQUE PSORIASIS NOW HAVE A NEW Rx TREATMENT OPTION appeared first on Good News!.

NIH study advances personalized immunotherapy for metastatic breast cancer

An experimental form of immunotherapy that uses an individual’s own tumor-fighting immune cells could potentially be used to treat people with metastatic breast cancer, according to results from an ongoing clinical trial led by researchers at the National Cancer Institute’s (NCI) Center for Cancer Research, part of the National Institutes of Health. Many people with metastatic breast cancer can mount an immune reaction against their tumors, the study found, a prerequisite for this type of immunotherapy, which relies on what are called tumor-infiltrating lymphocytes (TILs).

In a clinical trial of 42 women with metastatic breast cancer, 28 (or 67%) generated an immune reaction against their cancer. The approach was used to treat six women, half of whom experienced measurable tumor shrinkage. Results from the trial appeared Feb. 1, 2022, in the Journal of Clinical Oncology.

“It’s popular dogma that hormone receptor–positive breast cancers are not capable of provoking an immune response and are not susceptible to immunotherapy,” said study leader Steven A. Rosenberg, M.D., Ph.D., chief of the Surgery Branch in NCI’s Center for Cancer Research. “The findings suggest that this form of immunotherapy can be used to treat some people with metastatic breast cancer who have exhausted all other treatment options.”

Immunotherapy is a treatment that helps a person’s own immune system fight cancer. However, most available immunotherapies, such as immune checkpoint inhibitors, have shown limited effectiveness against hormone receptor–positive breast cancers, which are the majority of breast cancers.

The immunotherapy approach used in the trial was pioneered in the late 1980s by Dr. Rosenberg and his colleagues at NCI. It relies on TILs, T cells that are found in and around the tumor.

TILs can target tumor cells that have specific proteins on their surface, called neoantigens, that the immune cells recognize. Neoantigens are produced when mutations occur in tumor DNA. Other forms of immunotherapy have been found to be effective in treating cancers, such as melanoma, that have many mutations, and therefore many neoantigens. Its effectiveness in cancers that have fewer neoantigens, such as breast cancer, however, has been less clear.

The results of the new study come from an ongoing phase 2 clinical trial being carried out by Dr. Rosenberg and his colleagues. This trial was designed to see if the immunotherapy approach could lead to tumor regressions in people with metastatic epithelial cancers, including breast cancer. In 2018, the researchers showed that one woman with metastatic breast cancer who was treated in this trial had complete tumor shrinkage, known as a complete response.

In the trial, the researchers used whole-genome sequencing to identify mutations in tumor samples from 42 women with metastatic breast cancer whose cancers had progressed despite all other treatments. The researchers then isolated TILs from the tumor samples and, in lab tests, tested their reactivity against neoantigens produced by the different mutations in the tumor.

Twenty-eight women had TILs that recognized at least one neoantigen. Nearly all the neoantigens identified were unique to each patient.

“It’s fascinating that the Achilles’ heel of these cancers can potentially be the very gene mutations that caused the cancer,” said Dr. Rosenberg. “Since that 2018 study, we now have information on 42 patients, showing that the majority give rise to immune reactions.”

For the six women treated, the researchers took the reactive TILs and grew them to large numbers in the lab. They then returned the immune cells to each patient via intravenous infusion. All the patients were also given four doses of the immune checkpoint inhibitor pembrolizumab (Keytruda) before the infusion to prevent the newly introduced T cells from becoming inactivated.

After the treatment, tumors shrank in three of the six women. One is the original woman reported in the 2018 study, who remains cancer free to this day. The other two women had tumor shrinkage of 52% and 69% after six months and 10 months, respectively. However, some disease returned and was surgically removed. Those women now have no evidence of cancer approximately five years and 3.5 years, respectively, after their TIL treatment.

The researchers acknowledged that the use of pembrolizumab, which has been approved for some early-stage breast cancers, may raise uncertainties about its influence on the outcome of TIL therapy. However, they said, treatment with such checkpoint inhibitors alone has not led to sustained tumor shrinkage in people with hormone receptor–positive metastatic breast cancer.

Dr. Rosenberg said that with the anticipated opening early this year of NCI’s new building devoted to cell-based therapies, he and his colleagues can begin treating more individuals with metastatic breast cancer as part of the ongoing clinical trial. He noted that this new immunotherapy approach could potentially be used for people with other types of cancer as well.

“We’re using a patient’s own lymphocytes as a drug to treat the cancer by targeting the unique mutations in that cancer,” he said. “This is a highly personalized treatment.”

About the Center for Cancer Research (CCR): CCR comprises nearly 250 teams conducting basic, translational, and clinical research in the NCI intramural program — an environment supporting innovative science aimed at improving human health. CCR’s clinical program is housed at the NIH Clinical Center — the world’s largest hospital dedicated to clinical research. For more information about CCR and its programs, visit ccr.cancer.gov.

About the National Cancer Institute (NCI): NCI leads the National Cancer Program and NIH’s efforts to dramatically reduce the prevalence of cancer and improve the lives of cancer patients and their families, through research into prevention and cancer biology, the development of new interventions, and the training and mentoring of new researchers. For more information about cancer, please visit the NCI website at cancer.gov or call NCI’s contact center, the Cancer Information Service, at 1-800-4-CANCER (1-800-422-6237).

About the National Institutes of Health (NIH): NIH, the nation’s medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit nih.gov

#cancer #rosenberg #national #institute #health #research #breast #immunotherapy #patients #metastatic #tumor #fight #lymphocytes #oncology #infiltrating #immune #response #cells #dna #science

The post National Cancer Institute Researcher — Exciting Finding in Fight Against Breast Cancer (And Potentially Others) appeared first on Good News!.

E-mail this link to your Friends

Black Tie International Magazine:

2022 Is The Year Of The Tiger And The Year Of LifeWater

2022

Is The Year Of The Tiger

And

The Year Of LifeWater

We have entered the year of the tiger,
this brings with it having courage to take risks and go on adventures.

Not to mention finding the zest in life again and bringing more generosity to ourselves and those around us.

Last year changed our reality and ground ourselves in it.
And before that, 2020 was all about survival.

But this year brings big changes so don’t be scared if your life is suddenly uprooted, but don’t fall back into fear and survival,
this is the time to take a leap of faith!

With all these changes jumping out through the year,
our stress levels may shoot through the roof and
this could be a big factor in our health throughout 2022.

Taking this year to go back to the earth,
four natural foods can help us flourish from the inside out.

These are:

Ginger,

a popular root that can reduce pain, help you look younger,
reduce nausea and may help protect against cancer.

Siberian ginseng,

which can improve athletic performance and the ability to do work
and can also be used to boost the immune system,
prevent colds, and increase appetite.

Vitamin C

which is important to help protect your memory and thinking as you age.
On top of this it may reduce your risk of chronic disease
as well as boost immunity.

And lastly, Curcumin,

the main active ingredient in turmeric.
Curcumin is a natural anti-inflammatory compound
and can increase the antioxidant capacity of the body.

The above is just a few of the health benefits of the four superfoods above.

And these superfoods

can all be found in the new health drink hitting the market this year;

MXQ LifeWater!

Haven’t heard of it?

Soon you will as everyone is talking about it.

Whether it’s helping you to get up in the morning without caffeine, or helping you power through your workout,

LifeWater

will help you get there as you transform during the year of the tiger.

The tiger is related to rule (masculine, active) energy and likes to do things by their own means.

Taking this energy with the power of LifeWater

can help you have the energy and immunity to build a great life this year.

Looking deeper into

MXQ Life water,

you can see what truly makes this drink different to others on the market.

Nobel Prize nominee

Jerry Thornthwaite’s NutraNaNoSphere (NNS) technology

is something never seen before.

The NNS is  over 500 times smaller than a human red blood cell
and wraps the active ingredients in each bottle of LifeWater to be able bypass the stomach and be delivered directly into the bloodstream and be delivered throughout the body.

This new technology caught the attention of
Dr. Ma Xiaoqiu (Famous chinese author, singer and humanitarian)
who put her investment behind this new discovery,

and Rob Davidson (creator of CURE Pharma)
to become the current CEO of MXQ Lifewater.

On top of this, LifeWater comes in convenient droppers
so you can add this technology to your favorite food and drinks
and still keep the same benefits!

LifeWater

is pulling the attention of many around the world
and proving to be the next great health drink.

In the year of 2022
when the tiger reigns and it’s a time of transformation,
this may be the perfect time to transform your health and wellness.

Starting from the inside out,

let’s make 2022 a year that changes our lives.

Back to Wellness

The post 2022 Is The Year Of The Tiger And The Year Of LifeWater!! appeared first on Good News!.

PUZZLING SKIN CONDITION AFFECTS MORE THAN MEETS THE EYE
THE HIDDEN REALITY OF LIVING WITH A CHRONIC SKIN DISEASE

Hidradenitis suppurativa (HS) is an under-recognized and chronic inflammatory skin condition caused by an overactive immune system that can often go undiagnosed or misdiagnosed for years. The symptoms of HS include recurrent, painful abscesses and lesions and can have a significant physical, mental and social impact. HS can be progressive and increase in severity over time.

HS also presents itself in sensitive areas like the armpits, groin and under the breasts and buttocks, so it may be hidden by clothing – leaving many to suffer in silence. Further, the lack of awareness around this disease may lead to patients going undiagnosed or misdiagnosed for seven or more years. Patients may visit a number of doctors before finding a dermatologist with experience in managing HS to confirm diagnosis and determine a plan that best fits their specific needs.

Dr. Joslyn Kirby, a dermatologist with Penn State University, will bring greater understanding about HS by sharing how it’s more than just an inflammatory skin disease. Dr. Kirby will also discuss the importance for HS patients – along with their caregivers – to advocate for their care and seek out a dermatologist with experience treating HS who can help patients to receive an accurate diagnosis and appropriate treatment options.

Interview courtesy: AbbVie Inc.

#november #healthy #skin #month #condition #meets #eyes #eye #chronic #disease #hidradenitis #suppurativa #hs #inflammatory #overactive #immune #system #undiagnosed #misdiagnosed #symptoms #recurrent #painful #abscesses #lesions #physical #mental #social #impact #increase #dermatologist #penn #state #university #psu #caregivers #treatment

The post NOVEMBER IS NATIONAL HEALTHY SKIN MONTH appeared first on Good News!.

Please Share this message to your friends and family to make them aware about this blessing in the form of TEA in your kitchen.

The post Breaking News from CNN :- appeared first on Good News!.